Grupo Espanol De Tumores Neuroendocrinos

This study compares two schedules of the radioactive drug Lu177-Dotatate in 166 people with slow-growing midgut neuroendocrine tumors. One group gets the drug every 8 weeks (standard), the other every 16 weeks. The goal is to see if the less frequent schedule causes fewer blood-r…

Researchers are testing sacituzumab govitecan, an antibody-drug conjugate, in adults with advanced differentiated or anaplastic thyroid cancer that has stopped responding to radioactive iodine. The drug targets TROP-2, a protein found at high levels on these cancer cells. The tri…

This Phase 3 trial tests whether a radioactive drug called 177Lu-edotreotide works better than the standard drug everolimus for people with advanced neuroendocrine tumors of the lung or thymus. About 170 participants will receive either six cycles of the radioactive therapy or da…